Company intelligence / Profile preview
J2H Biotech
Suwon-si, Gyeonggi-do, South Koreaj2hbio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
J2H-1702 is currently in Phase 2 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with a 25% phase transition success rate. J2H-1701 is in Phase 1 for Hepatitis C.
- Therapeutic areas
- PulmonologyMetabolic DisordersOncologyNeurologyInfectious Diseases
- Modalities
- Small moleculesProteolysis-targeting chimeras (PROTAC)
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Institut Pasteur Korea (IPK)Shinhan Venture Investment
Beyond the preview
Go deeper on J2H Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on J2H Biotech.